EverLife Capital is an independent research publication. I write it because I'm obsessed with the science of aging, I'm personally tracking my own biology, and I believe the sector warrants serious research attention. But nothing I write here - not a company analysis, not a framework score, not a research ranking - is investment advice. It's not a recommendation to buy, sell, or hold anything. It's not a solicitation. It's not an offer to sell any security or investment product. It's one person sharing his research and his thinking. What you do with that is entirely your decision.
EverLife Capital is published by Consult Us, LLC, a Wyoming limited liability company. I am the author. Neither Consult Us, LLC nor I am registered as an investment adviser with the U.S. Securities and Exchange Commission, any state securities authority, or any non-U.S. regulator. I have no formal advisory relationship with any reader. Reading this newsletter does not make me your adviser, your fiduciary, your broker, your attorney, or your financial planner. If you need any of those things, please go find a licensed professional.
The Hypothetical Research Tracker - what it actually is
I maintain a Hypothetical Research Tracker as part of the 25-Gate Framework (currently v3.6). It's a structured exercise in applying the framework to real companies over time. Think of it as a research notebook with discipline imposed on it.
I want to be direct about what it is and isn't:
No real capital is deployed.
No actual trades are executed.
No positions are held in the Tracker for me or for any reader.
No pooled vehicle exists. No subscriber capital is accepted, managed, or solicited.
The Tracker is not a model portfolio, investment model, simulated account, managed account, or performance reporting system.
Any reference to weightings, milestones, or framework outcomes is an organizational research tool, not a return projection.
The framework is published publicly so readers can evaluate the research process over time. Past framework outcomes do not predict future results of any kind. The Tracker is illustrative only.
Biotech investing is genuinely risky. Here's what that means in practice.
Most drug candidates that enter clinical trials never get approved. A company can have beautiful science, a world-class team, and compelling preclinical data, and still fail a Phase 2 trial. One failure can wipe out most or all of the company's perceived value. The 25-Gate Framework exists to organize information about companies systematically, but it does not eliminate risk and does not predict outcomes. There are no guarantees in this sector.
Early-stage private biotech investments are also illiquid. Investors can be locked up for years and diluted by subsequent financing rounds. The company might run out of money before it reaches the next milestone. These are normal outcomes in this space, not edge cases.
Certain private-company investments discussed may be legally restricted to accredited investors under applicable securities laws.
My conflicts of interest - disclosed upfront and every time
I personally hold equity positions in two private longevity biotechnology companies:
Repair Biotechnologies. I acquired equity through direct participation. Repair Biotechnologies is also tracked within the Hypothetical Research Tracker. This is a disclosed conflict whenever Repair Biotechnologies or its mechanism class is discussed.
Yuva Biosciences. I hold a separate personal equity position. Yuva Biosciences is not included in the Hypothetical Research Tracker. This is a disclosed conflict whenever Yuva Biosciences or its mechanism class is discussed.
These holdings are personal to me. They are not held by Consult Us, LLC, and they are separate from the Hypothetical Research Tracker as a research instrument. My holdings and views may change over time without notice, and there is no obligation to update prior content.
Here's my commitment: every time I write about a company in which I hold a personal position, I intend to disclose that prominently at the top of that article. Additional positions, if I take them, will be disclosed the same way.
I have not been paid by any company to cover them. No cash, no equity grants, no free access to products, no speaking fees contingent on favorable coverage. EverLife Capital may receive compensation from affiliate relationships, sponsorships, advertising, or other commercial arrangements in the future, and any material compensation relationships will be disclosed in connection with relevant content. As of the date above, no such relationships exist.
What I can't promise about accuracy
I do my best to get the facts right - company stages, financing rounds, scientific claims, regulatory status. But this sector moves fast. A company I describe as pre-IND this month might file an IND next month. A clinical trial I describe as ongoing might read out before the next issue. I'm not going to update every prior article every time something changes, though I'll flag material changes in subsequent issues when they materially affect the research analysis.
I rely on publicly available information - press releases, academic publications, SEC filings, investor communications, analyst commentary, management statements. Those sources can contain errors and have not been independently verified by EverLife Capital. The publication may contain errors, omissions, outdated information, or inaccuracies despite reasonable efforts to maintain accuracy.
I'm not an insider at any of the companies I cover, and I don't have access to non-public information. Everything I write is based on what any serious outside observer could find.
You should not rely exclusively on information presented in EverLife Capital when making financial, investment, medical, legal, tax, or business decisions.
The bottom line on liability
I'm sharing my personal research and experience. I'm not responsible for investment decisions you make on the basis of what you read here. To the fullest extent the law allows, Consult Us, LLC and I disclaim liability for any losses, damages, or outcomes - financial or otherwise - that result from your use of or reliance on this publication. This publication is provided as-is, with no warranty of accuracy, completeness, or fitness for any purpose.
Your use of EverLife Capital does not create a fiduciary, advisory, brokerage, attorney-client, or medical-provider relationship.
One more thing on intellectual property
The 25-Gate Framework, the scoring methodology, the tier structure, the Hypothetical Research Tracker concept, the L-45 filter, and all original written content in EverLife Capital are owned by Consult Us, LLC. You can quote briefly with attribution. You can't reproduce, redistribute, or republish material wholesale without prior written permission.
These disclosures may be updated as positions or business circumstances change. Material changes will be noted at the top of the relevant issue. For complete legal terms, see the Terms of Use and the Privacy Policy.
This publication is impersonal and not tailored to the investment needs of any specific person.